Jump to content
RemedySpot.com

The New Valium?

Rate this topic


Guest guest

Recommended Posts

Guest guest

http://www.readability.com/mobile/articles/yakrpzsb

neuroskeptic.blogspot.com

The New Valium?

by Neuroskeptic  •  Aug. 3, 2011

Antipsychotics, originally designed to control the hallucinations and delusions

seen in schizophrenia, have been expanding their domain in recent years.

Nowadays, they're widely used in bipolar disorder, depression, and as a new

paper reveals, increasingly in anxiety disorders as well.

The authors, Comer et al, looked at the NAMCS survey, which provides yearly data

on the use of medications in visits to office-based doctors across the USA.

Back in 1996, just 10% of visits in which an anxiety disorder was diagnosed

ended in a prescription for an antipsychotic. By 2007 it was over 20%. No

atypical is licensed for use in anxiety disorders in the USA, so all of these

prescriptions are off-label.

Not all of these prescriptions will have been for anxiety. They may have been

prescribed to treat psychosis, in people who also happened to be anxious.

However, the increase was accounted for by the rise in non-psychotic patients,

and there was a rise in the rate of people with only anxiety disorders.

The increase was driven by the newer, " atypical " antipsychotics.

Whether the modern trend for prescribing antipsychotics for anxiety is a good or

a bad thing, is not for us to say. The authors discuss various concerns ranging

from the side effects (obesity, diabetes and more), to the fact that there have

only been a few clinical trials of these drugs in anxiety.

But what's really disturbing about these results, to me, is how fast the change

happened. Between 2000 and 2004, use doubled from 10% to 20% of anxiety visits.

That's an astonishingly fast change in medical practice.

Why? It wasn't because that period saw the publication of a load of large,

well-designed clinical trials demonstrating that these drugs work wonders in

anxiety disorders. It didn't.

But as Comer et al put it:

An increasing number of office-based psychiatrists are specializing in

pharmacotherapy to the exclusion of psychotherapy. Limitations in the

availability of psychosocial interventions may place heavy clinical demands on

the pharmacological dimensions of mental health care for anxiety disorder

patients.

In other words, antipsychotics may have become popular because they're the

treatment for people who can't afford anything better.

These data show that antipsychotics were over twice as likely to be prescribed

to African American patients; the poor i.e. patients with public health

insurance; and children under 18.

Comer JS, Mojtabai R, & Olfson M (2011). National Trends in the Antipsychotic

Treatment of Psychiatric Outpatients With Anxiety Disorders. The American

journal of psychiatry PMID: 21799067

Sent via BlackBerry by AT & T

Link to comment
Share on other sites

Guest guest

http://www.readability.com/mobile/articles/yakrpzsb

neuroskeptic.blogspot.com

The New Valium?

by Neuroskeptic  •  Aug. 3, 2011

Antipsychotics, originally designed to control the hallucinations and delusions

seen in schizophrenia, have been expanding their domain in recent years.

Nowadays, they're widely used in bipolar disorder, depression, and as a new

paper reveals, increasingly in anxiety disorders as well.

The authors, Comer et al, looked at the NAMCS survey, which provides yearly data

on the use of medications in visits to office-based doctors across the USA.

Back in 1996, just 10% of visits in which an anxiety disorder was diagnosed

ended in a prescription for an antipsychotic. By 2007 it was over 20%. No

atypical is licensed for use in anxiety disorders in the USA, so all of these

prescriptions are off-label.

Not all of these prescriptions will have been for anxiety. They may have been

prescribed to treat psychosis, in people who also happened to be anxious.

However, the increase was accounted for by the rise in non-psychotic patients,

and there was a rise in the rate of people with only anxiety disorders.

The increase was driven by the newer, " atypical " antipsychotics.

Whether the modern trend for prescribing antipsychotics for anxiety is a good or

a bad thing, is not for us to say. The authors discuss various concerns ranging

from the side effects (obesity, diabetes and more), to the fact that there have

only been a few clinical trials of these drugs in anxiety.

But what's really disturbing about these results, to me, is how fast the change

happened. Between 2000 and 2004, use doubled from 10% to 20% of anxiety visits.

That's an astonishingly fast change in medical practice.

Why? It wasn't because that period saw the publication of a load of large,

well-designed clinical trials demonstrating that these drugs work wonders in

anxiety disorders. It didn't.

But as Comer et al put it:

An increasing number of office-based psychiatrists are specializing in

pharmacotherapy to the exclusion of psychotherapy. Limitations in the

availability of psychosocial interventions may place heavy clinical demands on

the pharmacological dimensions of mental health care for anxiety disorder

patients.

In other words, antipsychotics may have become popular because they're the

treatment for people who can't afford anything better.

These data show that antipsychotics were over twice as likely to be prescribed

to African American patients; the poor i.e. patients with public health

insurance; and children under 18.

Comer JS, Mojtabai R, & Olfson M (2011). National Trends in the Antipsychotic

Treatment of Psychiatric Outpatients With Anxiety Disorders. The American

journal of psychiatry PMID: 21799067

Sent via BlackBerry by AT & T

Link to comment
Share on other sites

Guest guest

http://www.readability.com/mobile/articles/yakrpzsb

neuroskeptic.blogspot.com

The New Valium?

by Neuroskeptic  •  Aug. 3, 2011

Antipsychotics, originally designed to control the hallucinations and delusions

seen in schizophrenia, have been expanding their domain in recent years.

Nowadays, they're widely used in bipolar disorder, depression, and as a new

paper reveals, increasingly in anxiety disorders as well.

The authors, Comer et al, looked at the NAMCS survey, which provides yearly data

on the use of medications in visits to office-based doctors across the USA.

Back in 1996, just 10% of visits in which an anxiety disorder was diagnosed

ended in a prescription for an antipsychotic. By 2007 it was over 20%. No

atypical is licensed for use in anxiety disorders in the USA, so all of these

prescriptions are off-label.

Not all of these prescriptions will have been for anxiety. They may have been

prescribed to treat psychosis, in people who also happened to be anxious.

However, the increase was accounted for by the rise in non-psychotic patients,

and there was a rise in the rate of people with only anxiety disorders.

The increase was driven by the newer, " atypical " antipsychotics.

Whether the modern trend for prescribing antipsychotics for anxiety is a good or

a bad thing, is not for us to say. The authors discuss various concerns ranging

from the side effects (obesity, diabetes and more), to the fact that there have

only been a few clinical trials of these drugs in anxiety.

But what's really disturbing about these results, to me, is how fast the change

happened. Between 2000 and 2004, use doubled from 10% to 20% of anxiety visits.

That's an astonishingly fast change in medical practice.

Why? It wasn't because that period saw the publication of a load of large,

well-designed clinical trials demonstrating that these drugs work wonders in

anxiety disorders. It didn't.

But as Comer et al put it:

An increasing number of office-based psychiatrists are specializing in

pharmacotherapy to the exclusion of psychotherapy. Limitations in the

availability of psychosocial interventions may place heavy clinical demands on

the pharmacological dimensions of mental health care for anxiety disorder

patients.

In other words, antipsychotics may have become popular because they're the

treatment for people who can't afford anything better.

These data show that antipsychotics were over twice as likely to be prescribed

to African American patients; the poor i.e. patients with public health

insurance; and children under 18.

Comer JS, Mojtabai R, & Olfson M (2011). National Trends in the Antipsychotic

Treatment of Psychiatric Outpatients With Anxiety Disorders. The American

journal of psychiatry PMID: 21799067

Sent via BlackBerry by AT & T

Link to comment
Share on other sites

Guest guest

http://www.readability.com/mobile/articles/yakrpzsb

neuroskeptic.blogspot.com

The New Valium?

by Neuroskeptic  •  Aug. 3, 2011

Antipsychotics, originally designed to control the hallucinations and delusions

seen in schizophrenia, have been expanding their domain in recent years.

Nowadays, they're widely used in bipolar disorder, depression, and as a new

paper reveals, increasingly in anxiety disorders as well.

The authors, Comer et al, looked at the NAMCS survey, which provides yearly data

on the use of medications in visits to office-based doctors across the USA.

Back in 1996, just 10% of visits in which an anxiety disorder was diagnosed

ended in a prescription for an antipsychotic. By 2007 it was over 20%. No

atypical is licensed for use in anxiety disorders in the USA, so all of these

prescriptions are off-label.

Not all of these prescriptions will have been for anxiety. They may have been

prescribed to treat psychosis, in people who also happened to be anxious.

However, the increase was accounted for by the rise in non-psychotic patients,

and there was a rise in the rate of people with only anxiety disorders.

The increase was driven by the newer, " atypical " antipsychotics.

Whether the modern trend for prescribing antipsychotics for anxiety is a good or

a bad thing, is not for us to say. The authors discuss various concerns ranging

from the side effects (obesity, diabetes and more), to the fact that there have

only been a few clinical trials of these drugs in anxiety.

But what's really disturbing about these results, to me, is how fast the change

happened. Between 2000 and 2004, use doubled from 10% to 20% of anxiety visits.

That's an astonishingly fast change in medical practice.

Why? It wasn't because that period saw the publication of a load of large,

well-designed clinical trials demonstrating that these drugs work wonders in

anxiety disorders. It didn't.

But as Comer et al put it:

An increasing number of office-based psychiatrists are specializing in

pharmacotherapy to the exclusion of psychotherapy. Limitations in the

availability of psychosocial interventions may place heavy clinical demands on

the pharmacological dimensions of mental health care for anxiety disorder

patients.

In other words, antipsychotics may have become popular because they're the

treatment for people who can't afford anything better.

These data show that antipsychotics were over twice as likely to be prescribed

to African American patients; the poor i.e. patients with public health

insurance; and children under 18.

Comer JS, Mojtabai R, & Olfson M (2011). National Trends in the Antipsychotic

Treatment of Psychiatric Outpatients With Anxiety Disorders. The American

journal of psychiatry PMID: 21799067

Sent via BlackBerry by AT & T

Link to comment
Share on other sites

Join the conversation

You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.

Guest
Reply to this topic...

×   Pasted as rich text.   Paste as plain text instead

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

Loading...
×
×
  • Create New...